Proteomics International Laboratories Limited (PIQ.AX)

AUD 0.64

(-2.31%)

Market Cap (In AUD)

83.18 Million

Revenue (In AUD)

892.14 Thousand

Net Income (In AUD)

-6.37 Million

Avg. Volume

226.59 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.55-1.4
PE
-
EPS
-
Beta Value
0.443
ISIN
AU000000PIQ0
CUSIP
Q7781F108
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Richard John Lipscombe M.A., MA (Oxford), Ph.D., Ph.D., (London)
Employee Count
-
Website
https://www.proteomics.com.au
Ipo Date
2015-04-16
Details
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute and the Janssen Research & Development for the research of diabetic kidney disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma. The company was founded in 2001 and is based in Perth, Australia.